相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)-A proof of concept, open-label, nonrandomized phase IIa study.
Marc Van den Eynde et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
Joris B. W. Elbers et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E. Martinelli et al.
ANNALS OF ONCOLOGY (2020)
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).
Alexander Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
A.G. Sacco et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
M. Forster et al.
ANNALS OF ONCOLOGY (2020)
Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
E. Martinelli et al.
ANNALS OF ONCOLOGY (2020)
Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
S. Lonardi et al.
ANNALS OF ONCOLOGY (2020)
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
Yungan Tao et al.
EUROPEAN JOURNAL OF CANCER (2020)
Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Navid Sobhani et al.
CELLS (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Jesus Garcia-Foncillas et al.
FRONTIERS IN ONCOLOGY (2019)
668TiPPhase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
E Martinelli et al.
ANNALS OF ONCOLOGY (2019)
IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
R. Jotte et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
P. S. Chowdhury et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
Inhibitors of the PD-1 Pathway in Tumor Therapy
Martin W. LaFleur et al.
JOURNAL OF IMMUNOLOGY (2018)
Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal
Van K. Morris et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Jessica Moskovitz et al.
CURRENT ONCOLOGY REPORTS (2018)
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Amina Dahmani et al.
CANCERS (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
A Grothey et al.
ANNALS OF ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Richard M. Goldberg et al.
ESMO OPEN (2018)
A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC.
Patrick Mckay Boland et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Chiara Lazzari et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Fu-Shun Hsu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
Lin Wang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Steven Francis Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Zhi Ling Teo et al.
CANCER RESEARCH (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
Yuka Inoue et al.
CANCER SCIENCE (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment
Lubos Holubec et al.
ANTICANCER RESEARCH (2016)
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi et al.
CLINICAL CANCER RESEARCH (2016)
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Chiara Pozzi et al.
NATURE MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
Rika Fujii et al.
ONCOTARGET (2016)
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade
Nina Eissler et al.
ONCOIMMUNOLOGY (2016)
Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
John Pradeep Veluchamy et al.
PLOS ONE (2016)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Immunotherapy for Head and Neck Squamous Cell Carcinoma
David W. Schoppy et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Efficacy of cetuximab in the treatment of squamous cell carcinoma
Sophie Preneau et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2014)
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie et al.
BRITISH JOURNAL OF CANCER (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines
Eric Luedke et al.
SURGERY (2012)
The convergence of radiation and immunogenic cell death signaling pathways
Encouse B. Golden et al.
FRONTIERS IN ONCOLOGY (2012)
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
V. Gregoire et al.
ANNALS OF ONCOLOGY (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status
Nadine Lukan et al.
ONCOLOGY (2009)
The biological properties of cetuximab
Bruno Vincenzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism
Janine L. Coombes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
A unique subset of CD4+CD25high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment
Laura Strauss et al.
CLINICAL CANCER RESEARCH (2007)
Serial Killing of Tumor Cells by Human Natural Killer Cells - Enhancement by Therapeutic Antibodies
Rauf Bhat et al.
PLOS ONE (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
分享论文
